ClinicalTrials.gg
RecruitingNCT04531696UPTIDERUpdated Jun 28, 2024

UZ/KU Leuven Program for Post-mortem Tissue Donation to Enhance Research

An interventional study of Blood draw and Post-mortem tissue collection in Breast Cancer and Hereditary Diseases, sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-28.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Nov 2020; still recruiting 5 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Breast Neoplasms by Universitaire Ziekenhuizen KU Leuven — 7 open to participants now, 8 under way, 1 of them phase 3. Breast Neoplasms · Universitaire Ziekenhuizen KU Leuven.

Planned enrollment
11th of 21
100 · median 100
Started
2020
with 2 others
No phase
13 of 31
4 open now
Registered
22nd of 31
by date

Among the 31 studies in Breast Neoplasms by Universitaire Ziekenhuizen KU Leuven, this one is the 11th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2020, is one of 13 with no phase, and was the 22nd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 31 studies in Breast Neoplasms by Universitaire Ziekenhuizen KU Leuven are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Breast Neoplasms by Universitaire Ziekenhuizen KU Leuven, or all of them as a file.
02

Study summary

UPTIDER is a prospective, interventional, non-Investigational Medicinal Product (non-IMP), non-commercial, single centre post-mortem tissue donation program for metastatic breast cancer patients or patients with a germline pathogenic variant with a moderate to high lifetime risk of breast cancer and at least one malignancy at time of death. The overarching objective of UPTIDER is (i) to unravel metastatic breast cancer evolution, biology, heterogeneity and treatment resistance and (ii) to assess pathogenicity and tumour biology in hereditary cancer syndromes with a high lifetime risk of breast cancer; both through extensive post-mortem multi-level and multi-region sample analysis.

03

Conditions studied

  • Breast Cancer
  • Hereditary Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years.
  • Signature of by the subject.
  • breast cancer, or hereditary cancer syndrome with a moderate to high lifetime risk of breast cancer, for which the patient is treated/followed in UZ Leuven or treated in another hospital and referred to UZ Leuven specifically for the trial.

Additional inclusion criteria for the different substudies:

  • Pilot phase: no additional inclusion criteria.
  • ILC substudy: confirmed history of ILC.
  • IBC substudy: history of IBC, fulfilling the following criteria described by Dawood et al: rapid onset of breast erythema, oedema and/or peau d'orange and/or warm breast with or without an underlying palpable mass, duration of history of no more than 6 months, erythema occupying at least one-third of the breast and pathological confirmation of invasive carcinoma.
  • Hereditary cancer syndrome substudy: confirmed presence of a germline mutation known to be associated with a moderate to high lifetime risk of BC (e.g. known pathogenic variants in the genes BRCA1/2, CHEK2, TP53, PALB2) and presence of at least one malignant lesion at time of inclusion (of any origin) .
  • Other substudies: no additional inclusion criteria.

Exclusion criteria

Exclusion Criteria:

  • Presence of a transmissible disease that can form a risk to the health of researchers or others handling the body or patient samples. This includes but is not limited to the following infectious diseases: (HIV), active virus (HCV), encephalitis of unknown cause, Creutzfeldt-Jakob disease, rabies, active malaria, active tuberculosis, active SARS-CoV-2 infection.
  • Presence of any factors that could logistically or organizationally impede the study or the performance of sampling within a reasonable post-mortem time frame. This includes but is not limited to: residence of the subject at a faraway distance from the UZ Leuven hospital; residence of the subject on territory outside of Belgium; impossibility to notify the clinician confirming the death and the researchers within a reasonable time frame in case of death.

Additional exclusion criteria for the different substudies:

  • ILC substudy, IBC substudy: diagnosis of a other than breast cancer in the 5 years prior to inclusion. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin and in situ cervical carcinoma.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Other
    Standard

    UPTIDER consists of 8 substudies: 1. Pilot phase 2. Invasive Lobular Carcinoma (ILC) substudy 3. Inflammatory Breast Cancer (IBC) substudy 4. Molecular heterogeneity and treatment response substudy 5. Patient-derived xenograft (PDX) / Patient-derived Organoid (PDO) substudy 6. Metabolomics substudy 7. Liquid biopsy substudy 8. Hereditary cancer syndromes substudy The intervention, consisting of sample collection only, is identical in all substudies, however, the focus of downstream analysis of the samples may be different.

    Procedure: Blood draw · Procedure: Post-mortem tissue collection

Interventions

  • ProcedureBlood draw

    Blood draw at inclusion

  • ProcedurePost-mortem tissue collection

    Sample collection (both liquids, tumour tissue and non-tumour tissue) during post-mortem research autopsy

06

What researchers measure

Primary outcomes

  1. Percentage of patients consenting to participate in the pilot phase

    Should be equal to or above 50%

    Time frame: Baseline

  2. Median time elapsed between moment of death and start of the autopsy

    Should be equal to or less than 12h

    Time frame: During autopsy

  3. Median time elapsed between collection of first and last sample

    Should be equal to or less than 8h

    Time frame: During autopsy

  4. Percentage of metastatic organs sampled

    Should be equal to or more than 75%

    Time frame: During autopsy

  5. Percentage of samples with sufficient quality of DNA extracted

    A260/A280 ratio

    Time frame: During autopsy

  6. Percentage of samples with sufficient quality of RNA extracted

    RNA integrity number (RIN)

    Time frame: During autopsy

Secondary outcomes

  1. Concordance between TILs and clinical response to treatment

    Standard histopathological review

    Time frame: During autopsy

  2. Rate of T cell exhaustion

    RNA sequencing

    Time frame: During autopsy

  3. Number of mutations in each tumor lesion

    Whole exome sequencing

    Time frame: During autopsy

  4. Type of mutations in each tumor lesion

    Whole exome sequencing

    Time frame: During autopsy

  5. Percentage of Tumour Infiltrating Lymphocytes (TILs)

    Standard histopathological review

    Time frame: During autopsy

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Sep 2035, 178 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 178 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2020
First posted
Aug 28, 2020
StartActual
Nov 30, 2020
Primary completionEst.
Sep 2035
CompletionEst.
Sep 2035
Last update
Jun 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04531696
Responsible party
Sponsor
First posted
Aug 28, 2020
Start date
Nov 30, 2020
Primary completion
Sep 2035 (estimated)
Completion
Sep 2035 (estimated)
Last update
Jun 28, 2024

Study contacts

Giuseppe Floris, MD PhD
Contact
giuseppe.floris@uzleuven.be
003216336539
Christine Desmedt, PhD
Contact
christine.desmedt@kuleuven.be
003216193306 ext. www.ltbcr.be

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion